W. Michael Korn, Chief Medical Officer for Oncology at Invitae, shared a post on LinkedIn:
“Biocartis received FDA approval for the Idylla CDx MSI Test!
Congratulations to everybody at Biocartis for this significant achievement – I am proud to be part of the team!
This milestone was possible through close collaboration with our partners at Bristol Myers Squibb as part of the Check Mate-8HW trial. The Idylla CDx MSI Test was important for precisely identifying patients with mismatch-repair-deficient colorectal cancer for treatment with nivolumab with or without ipilimumab. The fast turnaround time (hours) and excellent accuracy of the test enable physicians to offer this treatment to patients with the highest likelihood of treatment response.
The approval highlights Biocartis‘ commitment to providing fast, relevant, and high-quality molecular test results to cancer patients and their providers worldwide.”
More posts featuring W Michael Korn on OncoDaily.